Table 4.
The area under the ROC curve (AUC) show the sensitivity and specificity of the known signatures in predicting the prognosis of BC patients.
| Author | Year | Gene Signature | AUC for OS |
|---|---|---|---|
| Li X, et al (47) | 2020 | 12 stemness-related lncRNA signature | 0.813 (5-year) |
| Lin Q, et al (48) | 2020 | 12 autophagy-related gene signature | 0.739(1-year), 0.727(3-year), 0.742(5-year), |
| Wang J, et al (49) | 2020 | four ISP gene signature | 0.742 (5-year) |
| Wang F, et al (50) | 2020 | six gene TMB-based signature | 0.705 (5-year) |
| Wang J, et al (51) | 2020 | 14-gene hypoxia−related signature | 0.728 (1-year), 0.726 (3-year), 0.736 (5-year) |
| Shen Y, et al (52) | 2020 | 11 immune-related lncRNA signature | 0.836 (5-year) |
| Xu H, et al (53) | 2020 | eight immune-related gene signature | 0.753 (3-year), 0.72 (5-year) |
| Zhao Y, et al (54) | 2020 | 27 immune-related gene signature | 0.844 (5-year) |
| Zhang D, et al (55) | 2020 | eight DNA repair–related gene signature | 0.708 (3-year), 0.704 (5-year) |
| Sun M, et al (56) | 2019 | eight lncRNA signature | 0.725 (1-year), 0.727 (3-year), 0.721 (5-year) |
| Kawaguchi, et al (57) | 2019 | three miRNA signature | 0.71 (5-year) |
| Lai J, et al (58) | 2019 | six microRNA model | 0.705 (3-year), 0.701 (5-year) |
| Liu L, et al (59) | 2019 | seven RNA signature | 0.705 (5-year) |
| Tao C, et al (60) | 2019 | seven DNA methylation site signature | 0.704 (5-year) |
| Feng L, et al (61) | 2018 | four methylated gene signature | 0.791 (5-year) |
OS, overall survival; ISP, immune, stromal, and proliferation; TMB, tumor mutation burden.